Publications by authors named "Harry L Messmore"

Claim this Profile
S
Simple scoring system for early management of heparin-induced thrombocytopenia.
Harry L Messmore, Nancy Fabbrini, Mary L Bird, Abdul M Choudhury, Miguel Cerejo

Clin Appl Thromb Hemost· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Alcohol consumption: benefit versus peril.
William H Wehrmacher, Harry L Messmore, Michael Collins

Compr Ther· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Wine, beer, and spirits metabolism.
Michael Collins, William H Wehrmacher, Harry L Messmore

Compr Ther· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rivaroxaban--an oral, direct Factor Xa inhibitor--has potential for the management of patients with heparin-induced thrombocytopenia.
Jeanine M Walenga, Margaret Prechel, Walter P Jeske, Debra Hoppensteadt, Jyothi Maddineni, Harry L Messmore

Br J Haematol· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Contaminated heparin preparations, severe adverse events and the contact system.
Eduardo Ramacciotti, Rakesh Wahi, Harry L Messmore

Clin Appl Thromb Hemost· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Human sexual intercourse.
William H Wehrmacher, Harry L Messmore

Compr Ther· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Contaminant in the recalled unfractionated heparin preparations: where is the problem?
Debra A Hoppensteadt, Rakesh Wahi, Cafer Adiguzel, Omer Iqbal, Eduardo Ramacciotti, Harry L Messmore

Clin Appl Thromb Hemost· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antigenic (immunogenic) profiling of bovine thrombin and its purified forms.
Jeanine M Walenga, Rodger L Bick, Harry L Messmore

Clin Appl Thromb Hemost· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Laboratory evaluation of the antiphospholipid syndrome.
Debra A Hoppensteadt, Nancy Fabbrini, Rodger L Bick, Harry L Messmore, Cafar Adiguzel

Hematol Oncol Clin North Am· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The immunogenic potential of generic version of low-molecular-weight heparins may not be the same as the branded products.
Jawed Fareed, Rodger L Bick, Gundu Rao, Samuel Z Goldhaber, Arthur Sasahara, Harry L Messmore

Clin Appl Thromb Hemost· January 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pain, analgesics, and the cardiovascular system.
William H Wehrmacher, Harry L Messmore, Waseem Haque

Compr Ther· December 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The classical vs nonclassical NSAIDs: can the reduction in pain overcome the thrombotic risk?
Wasim Haque, Jawed Fareed, William H Wehrmacher, Harry L Messmore

Compr Ther· December 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potential thrombogenic complications with the use of recombinant activated factor VII in combat trauma.
Jawed Fareed, Rodger L Bick, Craig Kessler, Harry L Messmore, Gundu Rao

Clin Appl Thromb Hemost· April 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Generic and commercial low molecular weight heparins.
Harry L Messmore

Clin Appl Thromb Hemost· July 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Thromboembolism in cancer patients: pathogenesis and treatment.
Matthew Adess, Robert Eisner, Sucha Nand, John Godwin, Harry L Messmore

Clin Appl Thromb Hemost· July 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pitfalls in warfarin therapy.
Harry L Messmore, Jawed Fareed, Rodger L Bick

Clin Appl Thromb Hemost· January 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Argatroban and lepirudin: clinical trials to clinical practice.
Harry L Messmore, Jawed Fareed, Jeanine M Walenga, Rodger L Bick

Clin Appl Thromb Hemost· October 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Society of Thoracic Surgeons practice guideline series: aspirin and other antiplatelet agents during operative coronary revascularization (executive summary).
Victor A Ferraris, Suellen P Ferraris, David J Moliterno, Philip Camp, Jeanine M Walenga, Harry L Messmore

Ann Thorac Surg· April 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antiplatelet agents: current drugs and future trends.
Harry L Messmore, Walter P Jeske, William Wehrmacher, Erwin Coyne, Sohrab Mobarhan

Hematol Oncol Clin North Am· February 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-Xa and anti-IIa drugs alter international normalized ratio measurements: potential problems in the monitoring of oral anticoagulants.
Mahmut Tobu, Omer Iqbal, Debra Hoppensteadt, Brian Neville, Harry L Messmore

Clin Appl Thromb Hemost· October 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differential prevalence of anti-heparin-PF4 immunoglobulin subtypes in patients treated with clivarin and heparin: implications in the HIT pathogenesis.
Sarfraz Ahmad, Brian Untch, Sylvia Haas, Debra A Hoppensteadt, Frank Misselwitz, Harry L Messmore

Mol Cell Biochem· March 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Heparin to pentasaccharide and beyond: the end is not in sight.
Harry L Messmore, William H Wehrmacher, Erwin Coyne, Jawed Fareed

Semin Thromb Hemost· February 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differential effects of DX-9065a, argatroban, and synthetic pentasaccharide on tissue thromboplastin inhibition test and dilute Russell's viper venom test.
Rolandas Gerbutavicius, Omer Iqbal, Harry L Messmore, William H Wehrmacher, Debra A Hoppensteadt

Clin Appl Thromb Hemost· October 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differential effects of clivarin and heparin in patients undergoing hip and knee surgery for the generation of anti-heparin-platelet factor 4 antibodies.
Sarfraz Ahmad, Sylvia Haas, Debra A Hoppensteadt, Helen Lietz, Ulrike Reid, Harry L Messmore

Thromb Res· October 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of a non-human primate sub-clinical model of heparin-induced thrombocytopenia: platelet responses to human anti-heparin-platelet factor 4 antibodies.
Brian Untch, Sarfraz Ahmad, Harry L Messmore, Christopher L Schultz, Qing Ma

Thromb Res· April 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis